Kaspar T, Schweiger A, Droz S, Marschall J
Department of Infectious Diseases and Prevention, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Antimicrob Resist Infect Control. 2015 Jul 25;4:31. doi: 10.1186/s13756-015-0071-6. eCollection 2015.
While multi-drug resistant organisms (MDRO) are a global phenomenon, there are significant regional differences in terms of prevalence. Traveling to countries with a high MDRO prevalence increases the risk of acquiring such an organism. In this study we determined risk factors for MDRO colonization among patients who returned from a healthcare system in a high-prevalence area (so-called transfer patients). Factors predicting colonization could serve as screening criteria to better target those at highest risk.
This screening study included adult patients who had been exposed to a healthcare system abroad or in a high-prevalence region in Switzerland over the past six months and presented to our 950-bed tertiary care hospital between January 1, 2012 and December 31, 2013, a 24-month period. Laboratory screening tests focused on Gram-negative MDROs and methicillin-resistant Staphylococcus aureus (MRSA).
A total of 235 transfer patients were screened and analyzed, of which 43 (18 %) were positive for an MDRO. Most of them yielded Gram-negative bacteria (42; 98 %), with only a single screening revealing MRSA (2 %); three screenings showed a combination of Gram-negative bacteria and MRSA. For the risk factor analysis we focused on the 42 Gram-negative MDROs. Most of them were ESBL-producing Escherichia coli and Klebsiella pneumoniae while only two were carbapenemase producers. In univariate analysis, factors associated with screening positivity were hospitalization outside of Europe (p < 0.001), surgical procedure in a hospital abroad (p = 0.007), and - on admission to our hospital - active infection (p = 0.002), antibiotic treatment (p = 0.014) and presence of skin lesions (p = 0.001). Only hospitalization outside of Europe (Odds Ratio, OR 3.2 (95 % CI 1.5- 6.8)) and active infection on admission (OR 2.7 (95 % CI 1.07- 6.6)) remained as independent predictors of Gram-negative MDRO colonization.
Our data suggest that a large proportion of patients (i.e., 82 %) transferred to Switzerland from hospitals in high MDRO prevalence areas are unnecessarily screened for MDRO colonization. Basing our screening strategy on certain criteria (such as presence of skin lesions, active infection, antibiotic treatment, history of a surgical procedure abroad and hospitalization outside of Europe) promises to be a better targeted and more cost-effective strategy.
虽然多重耐药菌(MDRO)是一种全球现象,但在流行率方面存在显著的地区差异。前往MDRO流行率高的国家会增加感染此类病菌的风险。在本研究中,我们确定了从高流行率地区的医疗系统返回的患者(即所谓的转诊患者)中MDRO定植的风险因素。预测定植的因素可作为筛查标准,以更好地针对风险最高的人群。
这项筛查研究纳入了在过去六个月中曾接触过国外或瑞士高流行率地区医疗系统的成年患者,这些患者于2012年1月1日至2013年12月31日期间(为期24个月)到我们拥有950张床位的三级护理医院就诊。实验室筛查测试主要针对革兰氏阴性MDRO和耐甲氧西林金黄色葡萄球菌(MRSA)。
共对235名转诊患者进行了筛查和分析,其中43名(18%)MDRO检测呈阳性。大多数检测出革兰氏阴性菌(42例;98%),仅有一次筛查发现MRSA(2%);三次筛查显示为革兰氏阴性菌和MRSA的混合感染。在风险因素分析中,我们重点关注42例革兰氏阴性MDRO感染病例。其中大多数是产超广谱β-内酰胺酶(ESBL)的大肠杆菌和肺炎克雷伯菌,只有两例是产碳青霉烯酶的菌株。在单因素分析中,与筛查阳性相关的因素包括在欧洲以外地区住院(p < 0.001)、在国外医院进行外科手术(p = 0.007),以及在我院入院时存在活动性感染(p = 0.002)、接受抗生素治疗(p = 0.014)和存在皮肤病变(p = 0.001)。只有在欧洲以外地区住院(优势比,OR 3.2(95%置信区间1.5 - 6.8))和入院时存在活动性感染(OR 2.7(95%置信区间1.07 - 6.6))仍然是革兰氏阴性MDRO定植的独立预测因素。
我们的数据表明,从MDRO高流行率地区的医院转诊至瑞士的患者中,很大一部分(即82%)无需进行MDRO定植筛查。基于某些标准(如存在皮肤病变、活动性感染、抗生素治疗、国外外科手术史和在欧洲以外地区住院)制定我们的筛查策略有望成为一种更具针对性和成本效益的策略。